111 (NASDAQ:YI - Get Free Report)'s stock had its "sell (d-)" rating reiterated by equities research analysts at Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.
111 Price Performance
YI remained flat at $7.54 during trading on Friday. 2,767 shares of the company's stock were exchanged, compared to its average volume of 24,774. 111 has a 52-week low of $4.15 and a 52-week high of $12.60. The stock has a market capitalization of $65.15 million, a PE ratio of -11.78 and a beta of 0.44. The stock has a 50 day moving average price of $7.78 and a two-hundred day moving average price of $7.52.
111 (NASDAQ:YI - Get Free Report) last posted its quarterly earnings data on Thursday, June 19th. The company reported ($0.20) EPS for the quarter. The firm had revenue of $486.35 million for the quarter.
Institutional Investors Weigh In On 111
Institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. lifted its position in shares of 111 by 43,619.9% during the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company's stock valued at $191,000 after acquiring an additional 305,339 shares during the period. FIL Ltd acquired a new position in shares of 111 during the 4th quarter valued at $450,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of 111 during the 1st quarter valued at $92,000. Deuterium Capital Management LLC acquired a new position in shares of 111 during the 1st quarter valued at $81,000. Finally, Napean Trading & Investment Co Singapore PTE Ltd acquired a new position in shares of 111 during the 4th quarter valued at $245,000. 21.32% of the stock is owned by institutional investors.
111 Company Profile
(
Get Free Report)
111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.
Recommended Stories
Before you consider 111, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 111 wasn't on the list.
While 111 currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
